BioLineRx (BLRX) EBT Growth (3y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 32.79% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 47.54% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -49.71% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 12.01% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 20.92% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -1.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 21.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.96% |
| Sep 30, 2025 | 38.94% |
| Jun 30, 2025 | 40.08% |
| Mar 31, 2025 | 33.97% |
| Dec 31, 2024 | 27.32% |
| Sep 30, 2024 | 17.39% |
| Jun 30, 2024 | 19.93% |
| Mar 31, 2024 | 12.88% |
| Dec 31, 2023 | -36.11% |
| Sep 30, 2023 | -37.54% |
| Jun 30, 2023 | -16.59% |
| Mar 31, 2023 | -12.50% |
| Dec 31, 2022 | 7.82% |
| Sep 30, 2022 | -4.94% |
| Jun 30, 2022 | -6.79% |
| Mar 31, 2022 | -5.79% |
| Dec 31, 2021 | 2.04% |
| Sep 30, 2021 | 0.79% |
| Jun 30, 2021 | -4.19% |
| Mar 31, 2021 | 6.95% |
| Dec 31, 2020 | 10.45% |
| Sep 30, 2020 | 14.52% |
| Jun 30, 2020 | -1.66% |
| Mar 31, 2020 | -9.12% |
| Dec 31, 2019 | -25.39% |
| Sep 30, 2019 | -10.38% |
| Jun 30, 2019 | -15.85% |
| Mar 31, 2019 | -10.69% |
| Dec 31, 2018 | -17.61% |
| Sep 30, 2018 | -20.84% |
| Jun 30, 2018 | -11.10% |
| Mar 31, 2018 | -13.82% |
| Dec 31, 2017 | -25.19% |
| Sep 30, 2017 | -57.16% |
| Jun 30, 2017 | -12.41% |
| Mar 31, 2017 | -9.95% |
| Dec 31, 2016 | -29.43% |
| Sep 30, 2016 | -18.67% |
| Jun 30, 2016 | 0.18% |
| Mar 31, 2016 | 14.31% |